Journal of NeuroVirology

, Volume 7, Issue 4, pp 386–390

Treatment of non-AIDS progressive multifocal leukoencephalopathy with cytosine arabinoside

Clinical Trial Report

Abstract

This open label study determined the outcome of non-AIDS progressive multifocal leukoencephalopathy patients treated with a standard dose of intravenous cytosine arabinoside. Nineteen patients with PML proven by brain biopsy or spinal fluid polymerase chain reaction were treated with intravenous cytosine arabinoside 2 mg/kg per day for 5 days and followed for neurologic outcome by neurologic examination and MRI scanning. Seven of 19 PML patients treated with cytosine arabinoside intravenously improved neurologically. The range of follow-up for these patients was 2.0 to 4.5 years. All were left with neurologic deficits but were functionally improved, and 6 of 7 were able to independently carry out the activities of daily living. Twelve PML patients showed no evidence of response and died rapidly of their disease after treatment (range, 8 days to 6 months). All who survived their neurologic disease recovered from treatment-induced pancytopenia. Cytosine arabinoside given intravenously to non-AIDS PML patients in this small study was associated with a 36% chance of developing stabilization at 1 year. Treatment was associated with significant bone marrow toxicity. The improvement in MRI scan changes in those patients who responded took 6 weeks or longer.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aksamit AJ Jr (1993). Nonradioactive in situ hybridization in progressive multifocal leukoencephalopathy. Mayo Clin Proc 68(9): 899–910.PubMedGoogle Scholar
  2. Bauer WR, Turel AP Jr, Johnson KP (1973). Progressive multifocal leukoencephalopathy and cytarabine. Remission with treatment. JAMA 226(2): 174–176.CrossRefPubMedGoogle Scholar
  3. Berger JR, Mucke L (1988). Prolonged survival and partial recovery in AIDS-associated progressive multifocal leukoencephalopathy. Neurology 38(7): 1060–1065.PubMedGoogle Scholar
  4. Brooks BR, Walker DL (1984). Progressive multifocal leukoencephalopathy. Neurol Clin 2(2): 299–313.PubMedGoogle Scholar
  5. Clifford DB, Yiannoutsos C, Glicksman M, Simpson DM, Singer EJ, Piliero PJ, Marra CM, Francis GS, McArthur JC, Tyler KL, Tselis AC, Hyslop NE (1993). HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology 52(3): 623–625.Google Scholar
  6. Hall CD, Dafni U, Simpson D, Clifford D, Wetherill PE, Cohen B, McArthur J, Hollander H, Yainnoutsos C, Major E, Millar L, Timpone J (1998). Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med 338(19): 1345–1351.CrossRefPubMedGoogle Scholar
  7. Kepes JJ, Chou SM, Price LW Jr (1975). Progressive multifocal leukoencephalopathy with 10-year survival in a patient with nontropical sprue. Report of a case with unusual light and electronmicroscopic features. Neurology 25(11): 1006–1012.PubMedGoogle Scholar
  8. Lidman C, Lindqvist L, Mathiesen T, Grane P (1991). Progressive multifocal leukoencephalopathy in AIDS. AIDS 5(8): 1039–1041.CrossRefPubMedGoogle Scholar
  9. Marriott PJ, O’Brien MD, Mackenzie IC, Janota I (1975). Progressive multifocal leucoencephalopathy: remission with cytarabine. J Neurol Neurosurg Psychiatry 38(3): 205–209.CrossRefPubMedGoogle Scholar
  10. Nicoli F, Chave B, Peragut JC, Gastaut JL (1992). Efficacy of cytarabine in progressive multifocal leucoencephalopathy in AIDS. Lancet 339(8788): 306.CrossRefPubMedGoogle Scholar
  11. O’Riordan T, Daly PA, Hutchinson M, Shattock AG, Gardner SD (1990). Progressive multifocal leukoencephalopathy-remission with cytarabine. J Infect 20(1): 51–54.CrossRefPubMedGoogle Scholar
  12. Peters AC, Versteeg J, Bots GT, Boogerd W, Vielvoye GJ (1980). Progressive multifocal leukoencephalopathy: immunofluorescent demonstration of simian virus 40 antigen in CSF cells and response to cytarabine therapy. Arch Neurol 37(8): 497–501.PubMedGoogle Scholar
  13. Portegies P, Algra PR, Hollak CE, Prins JM, Reiss P, Valk J, Lange JM (1991). Response to cytarabine in progressive multifocal leucoencephalopathy in AIDS. Lancet 337(8742): 680–681.CrossRefPubMedGoogle Scholar
  14. Price RW, Nielsen S, Horten B, Rubino M, Padgett B, Walker D (1983). Progressive multifocal leukoencephalopathy: a burnt-out case. Ann Neurol 13(5): 485–490.CrossRefPubMedGoogle Scholar
  15. Rockwell D, Ruben FL, Winkelstein A, Mendelow H (1976). Absence of immune deficiencies in a case of progressive multifocal leukoencephalopathy. Am J Med 61(3): 433–436.CrossRefPubMedGoogle Scholar
  16. Saxton C, Gailiunas P Jr, Helderman JH, Farkas RA, McCoy R, Diehl J, Sagalowsky A, Murphy FK, Ross ED, Silva FR (1984). Progressive multifocal leukoencephalopathy in a renal transplant recipient. Increased diagnostic sensitivity of computed tomographic scanning by double-dose contrast with delayed films. Am J Med 77(2): 333–337.CrossRefPubMedGoogle Scholar
  17. Schlitt M, Morawetz RB, Bonnin J, Chandra-Sekar B, Curtiss JJ, Diethelm AG Jr, Whelchel JD, Whitley RJ (1986). Progressive multifocal leukoencephalopathy: three patients diagnosed by brain biopsy, with prolonged survival in two. Neurosurgery 18(4): 407–414.CrossRefPubMedGoogle Scholar
  18. Steiger MJ, Tarnesby G, Gabe S, McLaughlin J, Schapira AH (1993). Successful outcome of progressive multifocal leukoencephalopathy with cytarabine and interferon. Ann Neurol 33(4): 407–411.CrossRefPubMedGoogle Scholar

Copyright information

© Journal of NeuroVirology, Inc. 2001

Authors and Affiliations

  1. 1.Department of NeurologyMayo ClinicRochesterUSA

Personalised recommendations